Seattle Genetics (SGEN) Said Lintuzumab Did Not Meet Primary Endpoint
Tweet Send to a Friend
Seattle Genetics, Inc. (Nasdaq: SGEN) said the phase IIb ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
